Berberine for weight loss: what the study found

How body weight and fat around the organs changed with berberine and placebo in adults with obesity.

Key points

  • In adults without diabetes who had obesity and fatty liver disease, berberine produced no additional weight loss over six months compared with placebo. Mean weight fell by about 1.8–1.9 kg in both groups, which received diet and activity advice. [1] See the evidence 1
  • The same study found no berberine advantage in reducing fat around the internal organs. For this group, the result shows no additional benefit on this measure. [1] See the evidence 1
  • Berberine should be avoided during pregnancy and breastfeeding; it is not given to infants. ANSES also recommends that people with diabetes, liver disease or heart disease avoid berberine supplements. [2] [3] [4] [5] [1] See the evidence 1

Practical guide

Check the conclusions and whether they apply to your situation.

The study compared berberine with placebo alongside the same diet and activity advice. Body weight and fat around the organs were assessed separately.

Key points

Why these conclusions

Body weight and fat around the organs

In the trial, adults without diabetes who had obesity and fatty liver disease took 500 mg berberine hydrochloride twice daily after meals or placebo for six months. Both groups received diet and physical-activity advice; mean weight fell by 1.8 and 1.9 kg respectively, with no additional reduction found with berberine. Confidence is low, 2 out of 4. [1]

The area of fat around the internal organs measured by CT decreased on average by 0.6% with berberine and 2.0% with placebo. No advantage of berberine was found; confidence is moderate, 3 out of 4. [1]

Before allocation, all participants took berberine for 30 days; those who could not tolerate it were excluded from the main phase. The weight and fat results come from one trial. [1]

Over six months, mean body weight fell by 1.8 kg with berberine and 1.9 kg with placebo. No additional weight loss was found with berberine: the adjusted difference was +0.05 kg, 95% confidence interval −0.74 to +0.84 kg.

ParameterData
ResultOver six months, mean body weight fell by 1.8 kg with berberine and 1.9 kg with placebo. No additional weight loss was found with berberine: the adjusted difference was +0.05 kg, 95% confidence interval −0.74 to +0.84 kg.
Participants337 adults without diabetes, with obesity and fatty liver disease; 169 received berberine and 168 placebo. Before allocation, all completed a 30-day berberine run-in; people who could not tolerate it were excluded from the main phase.
FormBerberine hydrochloride, 100 mg tablets
Dose500 mg twice daily after breakfast and dinner; 1 g/day in total
Dose basis500 mg twice daily after breakfast and dinner; 1 g/day in total
ComparatorPlacebo in matching tablets; both groups received diet and physical-activity advice
DurationSix months
Confidence2/4: Low confidence: this is an additional outcome of one trial in a specific group. The range of the estimate allows a small difference in either direction; the result does not mean weight did not change at all.
Evidence baserandomised trial
Sources[1]

The area of fat around the internal organs, measured by CT, decreased on average by 0.6% with berberine and 2.0% with placebo. No advantage of berberine was found; adjusted difference in changes: +1.38 percentage points, 97.5% confidence interval −2.43 to +5.18.

ParameterData
ResultThe area of fat around the internal organs, measured by CT, decreased on average by 0.6% with berberine and 2.0% with placebo. No advantage of berberine was found; adjusted difference in changes: +1.38 percentage points, 97.5% confidence interval −2.43 to +5.18.
Participants337 adults without diabetes, with obesity and fatty liver disease; 169 received berberine and 168 placebo. Before allocation, all completed a 30-day berberine run-in; people who could not tolerate it were excluded from the main phase.
FormBerberine hydrochloride, 100 mg tablets
Dose500 mg twice daily after breakfast and dinner; 1 g/day in total
Dose basis500 mg twice daily after breakfast and dinner; 1 g/day in total
ComparatorPlacebo in matching tablets; both groups received diet and physical-activity advice
DurationSix months
Confidence3/4: Moderate confidence: this is the primary outcome of a randomised trial with 337 participants. Missing measurements were accounted for statistically; a small difference between groups remains possible.
Evidence baserandomised trial
Sources[1]

Information from the source

Berberine may cause abdominal pain or discomfort, nausea, vomiting, constipation and diarrhoea. Berberine should be avoided during pregnancy and breastfeeding; it is not given to infants. It may contribute to dangerous bilirubin accumulation in an infant, with brain damage. The French agency ANSES also recommends that children and adolescents and people with diabetes, liver disease or heart disease avoid berberine supplements. Severe heart-rhythm disturbances with QT interval prolongation on an ECG have been reported after berberine use. In one case, large doses of cannabinoid oil were taken at the same time; in another, arrhythmia occurred in an older man taking 500 mg berberine daily. Case reports do not show how often this happens, but fainting or pronounced palpitations require urgent medical assessment. In the six-month BRAVO trial, serious adverse events were recorded in 6 of 169 participants with berberine and 2 of 168 with placebo; the difference was not statistically significant. These events are not equivalent to proven adverse effects of berberine. Before the main part of the study, people who could not tolerate the run-in were excluded. [2] [3] [4] [5] [1]

More details

Safety when choosing

Berberine can cause abdominal pain or discomfort, nausea, vomiting, constipation or diarrhoea. It is avoided during pregnancy and breastfeeding; fainting or pronounced palpitations require urgent medical assessment. [2] [3] [4] [5] [1]

Sources

  1. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41543854/
  2. In the News: Berberine. https://www.nccih.nih.gov/health/in-the-news-berberine
  3. ANSES Opinion on the safety of use of berberine-containing plants in the composition of food supplements — Request 2018-SA-0095. https://www.anses.fr/system/files/NUT2018SA0095EN.pdf
  4. Harmless herbs? A case report of acquired long QT syndrome and torsades de pointes in a patient taking herbal supplements. https://pmc.ncbi.nlm.nih.gov/articles/PMC9123311/
  5. Berberine Poisoning with Polymorphic Ventricular Tachycardia: A Case Report. https://pmc.ncbi.nlm.nih.gov/articles/PMC13517994/

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Berberine